A 52-year-old male smoker with 30 pack-years presents to the respiratory clinic with dyspnea on exertion. Spirometry shows FEV1 of 68% predicted with an FEV1/FVC ratio of 0.62, consistent with mild-to-moderate airflow obstruction. He is counseled on smoking cessation and successfully quits with behavioral support. Serial spirometry is planned to monitor his lung function trajectory. The structure marked **A** in the diagram represents the expected pattern of FEV1 decline after successful cessation. Based on the Lung Health Study, which of the following best describes the physiological change in FEV1 decline rate that occurs in sustained quitters?

Question

Accepted Answer

A. FEV1 decline slows from 60–90 mL/year (smoker rate) to approximately 30 mL/year (non-smoker rate). ## Why option 1 is correct

The Lung Health Study (Anthonisen NEJM 1994, long-term follow-up 2005) is the landmark randomized controlled trial that definitively established smoking cessation as the single most effective intervention to alter COPD natural history. In 5887 middle-aged smokers with mild-to-moderate airflow obstruction, sustained quitters demonstrated an FEV1 decline of approximately 30 mL/year—identical to never-smokers—compared to 60–66 mL/year in continuing smokers. This represents the structure marked **A**: cessation slows FEV1 decline to the non-smoker rate. After an initial small improvement of 50–100 mL in the first year post-cessation (reflecting resolution of acute inflammation), the decline rate returns to the normal age-related trajectory. The intervention group showed 18% lower all-cause mortality at 14.5-year follow-up, underscoring the profound public health impact of smoking cessation.

## Why each distractor is wrong

- **Option 2**: Misrepresents the magnitude and pattern of FEV1 change post-cessation. While there is a small initial improvement (50–100 mL) in the first year, FEV1 does not continue to improve progressively; it stabilizes and then declines at the normal non-smoker rate. Complete reversal of airway damage does not occur.
- **Option 3**: Contradicts the core finding of the Lung Health Study. Cessation demonstrably slows (not halts) FEV1 decline, proving that the accelerated decline in smokers is reversible to a significant degree and that airway remodeling is partially, not completely, irreversible.
- **Option 4**: Introduces an age cutoff (40 years) not supported by the Lung Health Study data. The benefit of cessation on FEV1 decline rate is consistent across the age range studied (middle-aged smokers) and is not restricted to younger individuals.

**High-Yield:** Smoking cessation is the SINGLE MOST EFFECTIVE intervention in COPD prevention and management—sustained quitters return to non-smoker FEV1 decline rates (~30 mL/year) within 1–2 years, reducing all-cause mortality by ~18% over 14 years.

[cite: Anthonisen NEJM 1994; Lung Health Study long-term follow-up 2005; Park's 28e; GATS-2 India tobacco prevalence]

Answer

B. FEV1 decline continues at the same accelerated rate regardless of cessation, as airway remodeling is irreversible

Answer

C. FEV1 decline slows only in patients under 40 years of age; older smokers show no benefit from cessation

Answer

D. FEV1 improves progressively by 200–300 mL per year and remains stable indefinitely

Explanation

Why option 1 is correct

Why each distractor is wrong

Practice similar questions